What is Novavax, Inc. (NVAX) stock price today?

Novavax, Inc. (NVAX) is currently trading at $7.61, up 2.01% today.

What is NVAX P/E ratio?

Novavax, Inc.'s P/E ratio is -13.81. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is NVAX return on equity (ROE)?

Novavax, Inc.'s return on equity (ROE) is 89.73%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is Novavax, Inc.'s market cap?

Novavax, Inc. has a market capitalization of $1.25B.

NASDAQ · Biotechnology

Novavax, Inc. (NVAX) Stock

$7.61 +2.01% NASDAQ: NVAX Healthcare

Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs.

Valuation

Metric	Value
Price	$7.61
Market Cap	$1.25B
P/E Ratio	-13.81
P/B Ratio	-8.41
P/S Ratio	2.06
EPS (TTM)	$-1.01
52-Week High	$11.97
52-Week Low	$6.20
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	89.73%
ROA	-8.42%
ROCE	-9.53%
Gross Margin	50.13%
Operating Margin	50.13%
Net Margin	-14.73%
Debt/Equity	-2.04
Current Ratio	2.13

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$198.0M	$1.6B	$556.0M	$682.0M	$1.1B
Operating Profit	$-1.7B	$-645.0M	$-567.0M	$-249.0M	$563.0M
Net Profit	$-1.7B	$-658.0M	$-545.0M	$-187.0M	$440.0M
EPS	$-23.44	$-8.42	$-5.41	$-1.23	$2.54
Op Margin	-853.6%	-40.3%	-101.8%	-36.5%	50.1%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$2.6B	$2.3B	$1.8B	$1.6B	$1.2B
Total Liabilities	$2.9B	$2.9B	$2.5B	$2.2B	$1.3B
Cash	$1.5B	$1.3B	$569.0M	$530.0M	$241.0M
Borrowings	$454.0M	$550.0M	$229.0M	$230.0M	$249.0M

Latest News

Novavax (NVAX) Stock Sinks As Market Gains: Here's Why Zacks · Jul 14, 2026 AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot Zacks · Jul 14, 2026 1 Cash-Heavy Stock on Our Buy List and 2 That Underwhelm StockStory · Jul 14, 2026 FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data Zacks · Jul 10, 2026 Novavax (NVAX) Leaves Russell Growth Indexes, Is The 32% Undervaluation Case Convincing? Simply Wall St. · Jul 10, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$323.0M	$-416.0M	$-714.0M	$-87.0M	$-245.0M
Investing Cash Flow	$43.0M	$-186.0M	$-118.0M	$-217.0M	$-84.0M
Financing Cash Flow	$25.0M	$-6.0M	$-4.0M	$1.0M	$-5.0M
Net Cash Flow	$880.0M	$-179.0M	$-765.0M	$-39.0M	$-289.0M
Free Cash Flow	$265.0M	$-509.0M	$-773.0M	$-100.0M	$-250.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.04
EV / EBITDA	2.13
FCF Yield	-19.98%
Quick Ratio	2.10
Interest Coverage	24.48
Return 1Y	-0.19%
Return 3Y	-1.82%
Return 5Y	-95.30%

Ownership

Insiders Held5.08%

Institutions Held69.46%

Institutions Float Held73.17%

Institutional Holder	Shares	Report Date
Shah Capital Management	14,845,097	2026-03-31
Blackrock Inc.	12,844,319	2026-03-31
State Street Corporation	8,970,518	2026-03-31
Shaw D.E. & Co., Inc.	7,709,858	2026-03-31
Vanguard Portfolio Management LLC	7,151,625	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
CVACCureVac N.V.	$4.66	+0.00%	5.69	$1.05B	0.00%
NKTR	$70.68	-0.13%	-6.95	$1.38B	0.00%
NTLA	$10.89	+2.06%	-3.55	$1.22B	0.00%
ORIC	$13.50	+4.41%	-5.39	$1.40B	0.00%
PGEN	$5.45	-1.45%	-2.99	$1.94B	0.00%

About Novavax, Inc.

Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.

Novavax, Inc. (NVAX) stock trades at $7.61 with a market capitalization of $1.25B. The stock is valued at a price-to-earnings (P/E) ratio of -13.81, price-to-book of -8.41, price-to-sales of 2.06. Over the past 52 weeks the stock has ranged between $6.20 and $11.97, and currently trades 36.4% below its 52-week high.

On profitability, Novavax, Inc. generates a return on equity (ROE) of 89.73% — well above the market average, a sign of a high-quality business, return on capital employed of -9.53%, an operating margin of 50.13%, a net profit margin of -14.73%.

Official website: www.novavax.com

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides